These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

583 related items for PubMed ID: 23317653

  • 1. Predictive value of spectral-domain optical coherence tomography features in assessment of visual prognosis in eyes with neovascular age-related macular degeneration treated with ranibizumab.
    Mathew R, Richardson M, Sivaprasad S.
    Am J Ophthalmol; 2013 Apr; 155(4):720-6, 726.e1. PubMed ID: 23317653
    [Abstract] [Full Text] [Related]

  • 2. Anatomical measures as predictors of visual outcomes in ranibizumab-treated eyes with neovascular age-related macular degeneration.
    Brown DM, Tuomi L, Shapiro H, Pier Study Group.
    Retina; 2013 Jan; 33(1):23-34. PubMed ID: 23073338
    [Abstract] [Full Text] [Related]

  • 3. Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results.
    Yamazaki T, Koizumi H, Yamagishi T, Kinoshita S.
    Ophthalmology; 2012 Aug; 119(8):1621-7. PubMed ID: 22551738
    [Abstract] [Full Text] [Related]

  • 4. Subfoveal fibrosis in eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab.
    Bloch SB, Lund-Andersen H, Sander B, Larsen M.
    Am J Ophthalmol; 2013 Jul; 156(1):116-124.e1. PubMed ID: 23664150
    [Abstract] [Full Text] [Related]

  • 5. Association between foveal microstructure and visual outcome in age-related macular degeneration.
    Shin HJ, Chung H, Kim HC.
    Retina; 2011 Sep; 31(8):1627-36. PubMed ID: 21606888
    [Abstract] [Full Text] [Related]

  • 6. Intravitreal ranibizumab injection for neovascular age-related macular degeneration in phakic versus pseudophakic eyes.
    Baek JS, Cho HJ, Cho SW, Kim CG, Kim JW.
    Retina; 2013 Mar; 33(3):467-73. PubMed ID: 23400082
    [Abstract] [Full Text] [Related]

  • 7. Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration.
    Kang HM, Kwon HJ, Yi JH, Lee CS, Lee SC.
    Am J Ophthalmol; 2014 May; 157(5):1013-21. PubMed ID: 24487050
    [Abstract] [Full Text] [Related]

  • 8. Intravitreal ranibizumab for exudative age-related macular degeneration with good baseline visual acuity.
    Saito M, Iida T, Kano M.
    Retina; 2012 Jul; 32(7):1250-9. PubMed ID: 22446886
    [Abstract] [Full Text] [Related]

  • 9. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.
    Brown DM, Chen E, Mariani A, Major JC, SAVE Study Group.
    Ophthalmology; 2013 Feb; 120(2):349-54. PubMed ID: 23131717
    [Abstract] [Full Text] [Related]

  • 10. Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration treated with ranibizumab.
    Cho HJ, Kim CG, Yoo SJ, Cho SW, Lee DW, Kim JW, Lee JH.
    Am J Ophthalmol; 2013 Jan; 155(1):118-126.e1. PubMed ID: 23022163
    [Abstract] [Full Text] [Related]

  • 11. Determinants of fixation in eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab.
    Mathew R, Pearce E, Sivaprasad S.
    Am J Ophthalmol; 2012 Mar; 153(3):490-496.e1. PubMed ID: 22071230
    [Abstract] [Full Text] [Related]

  • 12. Treat-and-extend bevacizumab for neovascular age-related macular degeneration: the importance of baseline characteristics.
    Rush RB, Simunovic MP, Vandiver L, Aragon AV, Ysasaga JE.
    Retina; 2014 May; 34(5):846-52. PubMed ID: 24240560
    [Abstract] [Full Text] [Related]

  • 13. CORRELATION BETWEEN OPTICAL COHERENCE TOMOGRAPHIC HYPERREFLECTIVE FOCI AND VISUAL OUTCOMES AFTER ANTI-VEGF TREATMENT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AND POLYPOIDAL CHOROIDAL VASCULOPATHY.
    Lee H, Ji B, Chung H, Kim HC.
    Retina; 2016 Mar; 36(3):465-75. PubMed ID: 26076214
    [Abstract] [Full Text] [Related]

  • 14. Results of intravitreal ranibizumab with a prn regimen in the treatment of extrafoveal and juxtafoveal neovascular membranes in age-related macular degeneration.
    Giacomelli G, Giansanti F, Finocchio L, Biagini I, Bacherini D, Virgili G, Menchini U.
    Retina; 2014 May; 34(5):860-7. PubMed ID: 24756034
    [Abstract] [Full Text] [Related]

  • 15. Epimacular brachytherapy for neovascular age-related macular degeneration (CABERNET): fluorescein angiography and optical coherence tomography.
    Jackson TL, Dugel PU, Bebchuk JD, Smith KR, Petrarca R, Slakter JS, Jaffe GJ, Nau JA, CABERNET Study Group.
    Ophthalmology; 2013 Aug; 120(8):1597-603. PubMed ID: 23490325
    [Abstract] [Full Text] [Related]

  • 16. The effect of fellow eye visual acuity on visual acuity of study eyes receiving ranibizumab for age-related macular degeneration.
    Zweifel SA, Saroj N, Shapiro H, Freund KB.
    Retina; 2012 Jul; 32(7):1243-9. PubMed ID: 22466461
    [Abstract] [Full Text] [Related]

  • 17. Intravitreal bevacizumab in the management of neovascular age-related macular degeneration: effect of baseline visual acuity.
    El-Mollayess GM, Mahfoud Z, Schakal AR, Salti HI, Jaafar D, Bashshur ZF.
    Retina; 2013 Oct; 33(9):1828-35. PubMed ID: 23615342
    [Abstract] [Full Text] [Related]

  • 18. Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration.
    Simader C, Ritter M, Bolz M, Deák GG, Mayr-Sponer U, Golbaz I, Kundi M, Schmidt-Erfurth UM.
    Ophthalmology; 2014 Jun; 121(6):1237-45. PubMed ID: 24684838
    [Abstract] [Full Text] [Related]

  • 19. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.
    Kodjikian L, Souied EH, Mimoun G, Mauget-Faÿsse M, Behar-Cohen F, Decullier E, Huot L, Aulagner G, GEFAL Study Group.
    Ophthalmology; 2013 Nov; 120(11):2300-9. PubMed ID: 23916488
    [Abstract] [Full Text] [Related]

  • 20. Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the LUMIERE study.
    Cohen SY, Mimoun G, Oubraham H, Zourdani A, Malbrel C, Queré S, Schneider V, LUMIERE Study Group.
    Retina; 2013 Mar; 33(3):474-81. PubMed ID: 23266880
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.